Sanara MedTech Inc.

Greetings and welcome to the Sonara Medtech Incorporated third quarter 2023 results and business update call. At this time all participants are on a listen only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Mr. Callan Nichols. Sir, you may begin.

Thank you, and good morning, everyone. I'd like to welcome you to Scenera MedTech's earnings conference call for the quarter ended September 30th, 2023. We issued our earnings released yesterday afternoon And I would like to highlight that we've posted today's deck on the investor relations page of our website. The supplemental deck, as well as a copy of the earnings release and form 10Q for the quarter ended September 30th, 2023 are available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Zach Clemming, Chief Executive Officer, and Mike McNeil, Chief Financial Officer to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call, in our press release, and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factors set forth in our most recent annual report on Form 10-K. as supplemented by the risk factors in our most recent quarterly report on Form 10-Q. Also, this conference call, our earnings release, and supplemental deck will reference certain non-GAAP measures. In that regard, I direct you to the reconciliation of these measures in the earnings materials that are available on our website. Now, I'd like to turn the call over to Ron.

Thank you, Kevin, and good morning, everyone. In Q3 2023, Cenera generated $16 million in net revenue, representing a 23% increase from the prior year period. The third quarter of 2023 was the eighth record revenue quarter for Cenera, and we continue to strengthen our sales infrastructure to support our growth strategy, as well as focus on increasing our penetration into hospitals where we have approvals and minimal revenue. I'd like to point out that by the end of the third quarter of 2023, We had generated more revenue than in all of 2022. Our loss before income taxes narrowed from 3.2 million to 1.1 million year over year in Q3. We had a net loss of 1.1 million in Q3 compared to a net loss of 1.5 million for the prior year period. The company also realized an adjusted EBITDA of $300,000 in Q3 compared to an adjusted EBITDA of negative 1.6 million. in Q3 2022. Mike will provide more details on our financial results in a few minutes. A key strategic milestone for the company in the third quarter was the acquisition of certain assets related to our collagen products business. The acquisition included all rights and ownership for human wound care uses for specific 510 cleared collagen-based wound care products, including Celerate RX and Hypol. This transaction has had multiple financial and strategic benefits, as you will hear about later. Turning to our product pipeline, subsequent to the end of the third quarter, we had several key achievements. In early October, we realized our first sale of Allocyte Plus Advanced Viable Bone Matrix. This product replaces our Allocyte Advanced Cellular Bone Matrix product and is processed by a well-established supplier with in-house processing capabilities and affords us greater control of our product supply. Scenera has a sufficient supply to meet current demands, and we believe measures are in place to provide product for our future requirements. In addition to our first sale of Allosite Plus, the company also realized its first sale of BioSurge Advanced Surgical Solution in early November 2023. We believe both of these products are key in our growth initiatives. As you know, Our ATM offering of common stock was paused at the end of Q1, and we did not currently have any plans to reactivate the ATM. Now, Zach Fleming will provide more details on our business.